Adjuvant Therapy With Nivolumab Versus Placebo in Patients With Resected Stage IIB/C Melanoma (Checkmate 76K)

被引：0

作者：

Gastman, Brian ^{[1
]}

Long, Georgina V. ^{[2
]}

Kirkwood, John M. ^{[3
]}

Hoeller, Christoph ^{[4
,5
]}

Weber, Jeffrey ^{[6
]}

Grob, Jean-Jacques ^{[7
]}

Mohr, Peter ^{[8
]}

Grabbe, Stephan ^{[9
]}

Dutriaux, Caroline ^{[10
]}

Chiarion-Sileni, Vanna ^{[11
]}

Mackiewicz, Jacek ^{[12
]}

Rutkowski, Piotr ^{[13
]}

Arenberger, Petr ^{[14
,15
]}

Quereux, Gaelle ^{[16
]}

Meniawy, Tarek ^{[17
]}

Ascierto, Paolo A. ^{[18
]}

van Akkooi, Alexander ^{[19
,20
]}

Durani, Piyush ^{[21
]}

Campigotto, Federico ^{[21
]}

Del Vecchio, Michele ^{[22
]}

机构：

[1] Cleveland Clin Fdn, Melanoma & High Risk Skin Canc Program, Cleveland, OH USA

[2] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[3] UPMC Hillman Canc Ctr, Melanoma & Skin Canc P, Med Dermatol, Pittsburgh, PA USA

[4] Med Univ Wien, Dermatol, Vienna, Austria

[5] Med Univ Wien, Skin Canc Ctr, Vienna, Austria

[6] NYU Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA

[7] Hop La Timone, Dermatol, Marseille, France

[8] Elbe Klinikum Buxtehude, Buxtehude, Germany

[9] Univ Mainz Med Ctr, Dermatol, Mainz, Germany

[10] Hop St Andre, Bordeaux, France

[11] IRCCS, Ist Oncol Veneto, Melanoma & Esophageal Oncol Unit, San Giovanni Rotondo, Italy

[12] Poznan Univ Med Sci, Poznan, Poland

[13] Maria Sklodowska Curie Natl Res Inst Oncol, Surg Oncol, Warsaw, Poland

[14] Charles Univ Prague, Fac Med 3, Dept Dermatovenereol, Prague, Czech Republic

[15] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic

[16] Nantes Univ Hosp, Nantes, France

[17] 15Sir Charles Gairdner Hosp, City Beach, WA USA

[18] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy

[19] Univ Sydney, Melanoma Inst Australia, Fac Med & Hlth, Sydney, NSW, Australia

[20] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[21] Bristol Myers Squibb, Global Oncol Clin Dev, New York, NY USA

[22] Fdn IRCCS Ist Nazl Tumori, Unit Melanoma Med Oncol, Milan, Italy

来源：

ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S35 / S36

页数：2

共 50 条

[21] MODELLING SURVIVAL OF PATIENTS WITH COMPLETELY RESECTED ADVANCED MELANOMA WITH ADJUVANT TREATMENT OF NIVOLUMAB VERSUS OBSERVATION
Batteson, R.
Hemstock, M.
Hart, R.
Kotapati, S.
Gooden, K. M.
Amadi, A.
VALUE IN HEALTH, 2018, 21 : S359 - S359
[22] Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Zimmer, Lisa
Livingstone, Elisabeth
Hassel, Jessica C.
Fluck, Michael
Eigentler, Thomas
Loquai, Carmen
Haferkamp, Sebastian
Gutzmer, Ralf
Meier, Friedegund
Mohr, Peter
Hauschild, Axel
Schilling, Bastian
Menzer, Christian
Kieker, Felix
Dippel, Edgar
Rosch, Alexander
Simon, Jan-Christoph
Conrad, Beate
Korner, Silvia
Windemuth-Kieselbach, Christine
Schwarz, Leonora
Garbe, Claus
Becker, Juergen C.
Schadendorf, Dirk
LANCET, 2022, 400 (10358): : 1117 - 1129
[23] Phase III KEYNOTE-716 Study of Pembrolizumab (KEYTRUDA®) as adjuvant Therapy for Patients with resected Stage IIB or IIC Melanoma: significant Improvement in distant metastasis-free Survival versus Placebo
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
[24] Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
Favre-Bulle, Andrea
Bencina, Goran
Zhang, Shujing
Jiang, Ruixuan
Andritschke, Daniel
Bhadhuri, Arjun
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 283 - 292
[25] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Ascierto, P. A.
Del Vecchio, M.
Merelli, B.
Gogas, H.
Arance Fernandez, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J. J.
Chiarion Sileni, V.
Marquez-Rodas, I.
Butler, M. O.
Di Giacomo, A. M.
Pe Benito, M.
Soomro, R.
Askelson, M.
Weber, J. S.
Larkin, J.
ANNALS OF ONCOLOGY, 2023, 34 : S656 - S656
[26] Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
Luke, Jason J.
Ascierto, Paolo A.
Khattak, Muhammad A.
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Wu, Xi Lawrence
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M. M.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1619 - 1624
[27] Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Ascierto, Paolo A.
Del Vecchio, Michele
Mandala, Mario
Gogas, Helen
Arance, Ana M.
Dalle, Stephane
Cowey, C. Lance
Schenker, Michael
Grob, Jean-Jacques
Chiarion-Sileni, Vanna
Marquez-Rodas, Ivan
Butler, Marcus O.
Maio, Michele
Middleton, Mark R.
de la Cruz-Merino, Luis
Arenberger, Petr
Atkinson, Victoria
Hill, Andrew
Fecher, Leslie A.
Millward, Michael
Khushalani, Nikhil, I
Queirolo, Paola
Lobo, Maurice
de Pril, Veerle
Loffredo, John
Larkin, James
Weber, Jeffrey
LANCET ONCOLOGY, 2020, 21 (11): : 1465 - 1477
[28] Nivolumab demonstrated superior disease-free Survival in the adjuvant Therapy in Patients with resected Carcinoma of the Esophagus or the gastroosophageal Junction versus Placebo
不详
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (11) : 641 - 641
[29] Adjuvant Nivolumab (NIVO) Versus Ipilimumab (IPI) in Resected Stage III/IV Melanoma: 3-Year Efficacy and Biomarker Results From the Phase 3 Checkmate 238 Trial
Weber, J.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Butler, M.
Maio, M.
Vetto, J.
Tang, H.
Saci, A.
de Pril, V.
Lobo, M.
Larkin, J.
Ascierto, P. A.
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S144 - S144
[30] Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)
Weber, Jeffrey S.
Mandala, Mario
Del Vecchio, Michele
Gogas, Helen
Arance, Ana M.
Cowey, C. Lance
Dalle, Stephane
Schenker, Michael
Chiarion-Sileni, Vanna
Marquez-Rodas, Ivan
Grob, Jean-Jacques
Butler, Marcus
Middleton, Mark R.
Maio, Michele
Atkinson, Victoria
Dummer, Reinhard
de Pril, Veerle
Qureshi, Anila
Larkin, James
Ascierto, Paolo A.
BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 41 - 42

← 1 2 3 4 5 →